:: Library Catalog

Imagen de Portada

Guardado en:

Detalles Bibliográficos
Autores principales:	Vivek Purohit, Kazuko Sagawa, Hao‐Jui Hsu, Joseph Kushner, Martin E. Dowty, Susanna Tse, Jian Lin, Andrew Blanchard, Arnab Mukherjee, Vu Le, Cheng Chang
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3313
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Is a Clinical Trial With a Non‐Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK
por: Jin Dong, et al.
Publicado: (2026)

Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future
por: Karen Rowland Yeo, et al.
Publicado: (2024)

Bioequivalence and Safety of Two Formulations of Tofacitinib Citrate Tablets in Healthy Chinese Volunteers under Fasting and Fed Conditions: Randomized, Open‐Label, 2‐Period, Single‐Dose, Crossover Trials
por: Yanping Liu, et al.
Publicado: (2024)

How PBPK Can Help to Understand Old Drugs and Inform their Dosing in Elderly: Amantadine Case Study
por: Olha Shuklinova, et al.
Publicado: (2024)

The Single‐Dose Pharmacokinetics of a Compounded Levetiracetam Formulation and Bioequivalence to a Commercial Formulation in Healthy Dogs
por: Aaron M. Paushter, et al.
Publicado: (2024)

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
por: Kenichi Umehara, et al.
Publicado: (2024)

Population Pharmacokinetics of Tigecycline in Critically Ill Patients and Optimal Dosage Regimens With Dose Simulations Based on Infection Type and Renal Function
por: Fen Yao, et al.
Publicado: (2025)

Optimizing Dosage in Pharmacotherapy—Missing the Forest for the Trees
por: Susan M. Abdel‐Rahman, et al.
Publicado: (2024)

Model‐Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate‐to‐Severe Ulcerative Colitis
por: Jessica Wojciechowski, et al.
Publicado: (2024)

Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data
por: Gaurav Bajaj, et al.
Publicado: (2025)

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
por: Arshdeep Singh, et al.
Publicado: (2025)

Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs
por: Atiqur Rahman, et al.
Publicado: (2024)

Pharmacokinetics of Intramuscularly Administered Ketamine at Subanaesthetic Dosage in Horses
por: Zoë Vandaele, et al.
Publicado: (2026)

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
por: Kunal S. Taskar, et al.
Publicado: (2025)

Age‐Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling
por: Md Masud Parvez, et al.
Publicado: (2024)

Getting the Dosage Right: A Vital Role for Clinical Pharmacology in the Era of Precision Medicine
por: Iris K. Minichmayr, et al.
Publicado: (2024)

Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
por: Wei Gao, et al.
Publicado: (2025)

Ticagrelor versus Adjusted‐Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention
por: Ming‐Lung Tsai, et al.
Publicado: (2024)

Reply to: “Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis”
por: Polly Paul, et al.
Publicado: (2025)

Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling
por: Friederike Kanefendt, et al.
Publicado: (2024)

Optimizing Linezolid Dosing by Renal Function: A Population Pharmacokinetic Study
por: Khue N. Y. Ha, et al.
Publicado: (2026)

Effects of Triazole Antifungal Agents on the Plasma Concentration and Dosage of Cyclosporin in Patients with Aplastic Anaemia
por: Yangxiu Tian, et al.
Publicado: (2024)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
por: Jatinder Kaur Mukker, et al.
Publicado: (2025)

Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy
por: Emiel Leegwater, et al.
Publicado: (2024)

A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients
por: Donald Irby, et al.
Publicado: (2025)

A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
por: Chi‐Chung Li, et al.
Publicado: (2024)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
por: Jessica D. Lee, et al.
Publicado: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
por: Jessica D. Lee, et al.
Publicado: (2025)

Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement
por: Irina Kareva, et al.
Publicado: (2025)

Pharmacokinetics, Optimal Dosages, and Withdrawal Time of Florfenicol in Cobia ( Rachycentron canadum ) After Oral Administration via Medicated Feed
por: Jou‐An Shih, et al.
Publicado: (2026)

A Pharmacokinetic‐Pharmacodynamic Approach to Propose an Amoxicillin Dosage Regimen for Treatment of Escherichia coli and Staphylococcus delphini Infections in Mink ( Neovison vison )
por: Amir Atabak Ronaghinia, et al.
Publicado: (2025)

Controlled Drug Release Systems for Cerebrovascular Diseases
por: Celia Martín‐Morales, et al.
Publicado: (2024)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
por: Anupam Kumar Singh, et al.
Publicado: (2025)

Assessment of Dosing Strategies for Pediatric Drug Products
por: Zachary L. Taylor, et al.
Publicado: (2024)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
por: Pardhu Bharath Neelam, et al.
Publicado: (2025)

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer
por: Emmanuel Chigutsa, et al.
Publicado: (2026)

Moving the Needle for Oncology Dose Optimization: A Call for Action
por: Karthik Venkatakrishnan, et al.
Publicado: (2024)

Dosing and Exposure of Vancomycin With Continuous Infusion: A Retrospective Study
por: Judith Y. M. N. Derijks‐Engwegen, et al.
Publicado: (2024)

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma
por: Ruben Malmberg, et al.
Publicado: (2025)

Establishment of the Drug Exposure Models in the Dosing Environment of Inhaled Preparations and Discussion on Contamination Prevention and Control Measures in the Dosing Procedure
por: Dan Zhang, et al.
Publicado: (2026)